TY - JOUR
T1 - Parkinson disease clinical subtypes
T2 - key features & clinical milestones
AU - Campbell, Meghan C.
AU - Myers, Peter S.
AU - Weigand, Alexandra J.
AU - Foster, Erin R.
AU - Cairns, Nigel J.
AU - Jackson, Joshua J.
AU - Lessov-Schlaggar, Christina N.
AU - Perlmutter, Joel S.
N1 - Funding Information:
Support for this work was provided by grants from NINDS (NS097437, NS075321, NS41509, NS058714, NS48924, P30 NS048056) and NIH NCRR (UL1RR024992); American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; Oertli Fund; Barnes-Jewish Hospital Foundation (BJHF) (Elliot Stein Family Fund & PD Research Fund), and Paula C and Rodger O Riney Foundation. We thank the study participants for their time and effort to aid our understanding of Parkinson disease. We also thank the study coordinators and research nurse coordinators, including Phil Lintzenich, Thomas Belcher, Jenny Zhen-Duan, Anja Pogarcic, My Vu, Barb Merz, Jenny Petros, Katharine Cummings, Selma Avdagic, Kelly McVey, Jacob Wolf, Chris Waller, and especially Johanna Hartlein, for assistance with data collection.
Funding Information:
Support for this work was provided by grants from NINDS (NS097437, NS075321, NS41509, NS058714, NS48924, P30 NS048056) and NIH NCRR (UL1RR024992); American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; Oertli Fund; Barnes‐Jewish Hospital Foundation (BJHF) (Elliot Stein Family Fund & PD Research Fund), and Paula C and Rodger O Riney Foundation.
Funding Information:
Dr. Campbell receives salary and research support from the NIH, American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA; McDonnell Center for Systems Neuroscience; Department of Radiology at WUSTL. She also received honoraria from the Department of Veterans Affairs and the Parkinson Foundation. Dr. Myers receives salary and research support from NIH. Ms. Weigand receives salary and research support from NSF. Dr. Foster receives salary and research support from the NIH and American Parkinson Disease Association (APDA) Advanced Research Center for PD at WUSTL; Greater St. Louis Chapter of the APDA. Dr. Cairns receives salary and research support from NIH and the University of Exeter. Dr. Jackson receives salary and research support from NIH and Washington University in St. Louis. Dr. Lessov‐Schlaggar receives salary and research support from NIH. Dr. Perlmutter receives salary and research support from NIH, Washington University in St. Louis, American Parkinson Disease Association (APDA), Greater St. Louis Chapter of the APDA, McDonnell Center for Higher Brain Function, Barnes‐Jewish Hospital Foundation, Huntington’s Disease Society of America, CHDI, MJ Fox Foundation, Fixel Foundation, Oertli Foundation, Riney Foundation and Washington University CTSA/ICTS. He also received honoraria from the American Academy of Neurology, University of Rochester, Parkinson Disease Foundation, St Louis Univ., Harvard, Univ. Michigan, Stanford, CHDI, Huntington Study Group.
Publisher Copyright:
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Objectives: Based on multi-domain classification of Parkinson disease (PD) subtypes, we sought to determine the key features that best differentiate subtypes and the utility of PD subtypes to predict clinical milestones. Methods: Prospective cohort of 162 PD participants with ongoing, longitudinal follow-up. Latent class analysis (LCA) delineated subtypes based on score patterns across baseline motor, cognitive, and psychiatric measures. Discriminant analyses identified key features that distinguish subtypes at baseline. Cox regression models tested PD subtype differences in longitudinal conversion to clinical milestones, including deep brain stimulation (DBS), dementia, and mortality. Results: LCA identified distinct subtypes: “motor only” (N = 63) characterized by primary motor deficits; “psychiatric & motor” (N = 17) characterized by prominent psychiatric symptoms and moderate motor deficits; “cognitive & motor” (N = 82) characterized by impaired cognition and moderate motor deficits. Depression, executive function, and apathy best discriminated subtypes. Since enrollment, 22 had DBS, 48 developed dementia, and 46 have died. Although there were no subtype differences in rate of DBS, dementia occurred at a higher rate in the “cognitive & motor” subtype. Surprisingly, mortality risk was similarly elevated for both “cognitive & motor” and “psychiatric & motor” subtypes compared to the “motor only” subtype (relative risk = 3.15, 2.60). Interpretation: Psychiatric and cognitive features, rather than motor deficits, distinguish clinical PD subtypes and predict greater risk of subsequent dementia and mortality. These results emphasize the value of multi-domain assessments to better characterize clinical variability in PD. Further, differences in dementia and mortality rates demonstrate the prognostic utility of PD subtypes.
AB - Objectives: Based on multi-domain classification of Parkinson disease (PD) subtypes, we sought to determine the key features that best differentiate subtypes and the utility of PD subtypes to predict clinical milestones. Methods: Prospective cohort of 162 PD participants with ongoing, longitudinal follow-up. Latent class analysis (LCA) delineated subtypes based on score patterns across baseline motor, cognitive, and psychiatric measures. Discriminant analyses identified key features that distinguish subtypes at baseline. Cox regression models tested PD subtype differences in longitudinal conversion to clinical milestones, including deep brain stimulation (DBS), dementia, and mortality. Results: LCA identified distinct subtypes: “motor only” (N = 63) characterized by primary motor deficits; “psychiatric & motor” (N = 17) characterized by prominent psychiatric symptoms and moderate motor deficits; “cognitive & motor” (N = 82) characterized by impaired cognition and moderate motor deficits. Depression, executive function, and apathy best discriminated subtypes. Since enrollment, 22 had DBS, 48 developed dementia, and 46 have died. Although there were no subtype differences in rate of DBS, dementia occurred at a higher rate in the “cognitive & motor” subtype. Surprisingly, mortality risk was similarly elevated for both “cognitive & motor” and “psychiatric & motor” subtypes compared to the “motor only” subtype (relative risk = 3.15, 2.60). Interpretation: Psychiatric and cognitive features, rather than motor deficits, distinguish clinical PD subtypes and predict greater risk of subsequent dementia and mortality. These results emphasize the value of multi-domain assessments to better characterize clinical variability in PD. Further, differences in dementia and mortality rates demonstrate the prognostic utility of PD subtypes.
UR - http://www.scopus.com/inward/record.url?scp=85087166805&partnerID=8YFLogxK
U2 - 10.1002/acn3.51102
DO - 10.1002/acn3.51102
M3 - Article
C2 - 32602253
AN - SCOPUS:85087166805
SN - 2328-9503
VL - 7
SP - 1272
EP - 1283
JO - Annals of Clinical and Translational Neurology
JF - Annals of Clinical and Translational Neurology
IS - 8
ER -